参一胶囊联合GP方案化疗治疗晚期非小细胞肺癌疗效观察-肿瘤学专业论文.docxVIP

泰山医学院硕士学位论文 泰山医学院硕士学位论文 万方数据 万方数据 参一胶囊联合 GP 方案化疗治疗晚期非小细胞肺癌疗效观察 研究生：李 芹 专 业：肿瘤学 导 师：肖宝荣 教授 中文摘要 目的 研究晚期非小细胞肺癌应用参一胶囊与 GP 方案联用的临床治疗效果。 方法 任意选择联合参一胶囊者 47 例，单用 GP 方案化疗患者 43 例，共 90 例晚期非 小细胞肺癌（Ⅳ期）患者，分别对用药 2 周期后进行胸部 CT、血癌胚抗原、鳞状细 胞相关抗原进行治疗前后的对比，观察肺部病灶大小变化、血清肿瘤标志物变化及用 药后不良反应，来比较 GP 方案联合参一胶囊与单用 GP 方案化疗治疗效果的不同及 不良反应的差别。 结果 治疗后，两组胸部 CT 病灶显示都较治疗前缩小，血清癌胚抗原及鳞状细胞相关 抗原均较前降低，联合用药组癌胚抗原及鳞状细胞相关抗原及肺部病灶变化更明显， 联合用药组化疗的不良反应较单用化疗组明显减轻。 结论 在晚期非小细胞肺癌治疗时应用 GP 方案联合参一胶囊证明能有更低副作用，更 高疗效。 关键词 参一胶囊 非小细胞肺癌 疗效 吉西他滨 顺铂 1 ASCO THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY Graduate student: LiQin AD industry : Oncology Guide teacher: Professor XiaoBaoRong Purpose ABSTACT Application study of advanced non-small cell lung cancer ShenYi capsule with GP scheme combination of clinical therapeutic effect. Methods Choose any joint 47 ShenYi capsule GP scheme of 43 patients with chemotherapy alone .A total of 90 cases of patients with advanced non-small cell lung cancer (Ⅳ period) Of medication, blood cancer embryo antigen after 2 cycles with chest CT, squamous cell related antigen contrast before and after treatment, observation of pulmonary lesions size changes, serum tumor markers, and adverse reactions after use .To compare GP solutions jointly ShenYi capsule on GP difference of curative effect and adverse reaction of chemotherapy Results After treatment, two groups of chest CT lesions showed relatively narrow before treatment ,Serum carcinoembryonic antigen and squamous cell related antigen than before .Combination of carcinoembryonic antigen and squamous cell related antigen and lung lesions change is more obvious.Combination chemotherapy group significantly reduce adverse reaction than chemotherapy alone group. Conclusion Application in advanced non-small cell lung cancer treatment GP joint ShenYi capsule scenarios that can have less side effect, higher curative effect Keywords ShenYi capsule; Non-small-cell lung cancer;Curative effect;Gemcitabine; Cisplatin 2 符号说明 英文缩写 NSCLC 英文全称 non-small-cell lung cancer 中